
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1)</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1)</strong></summary>
            <div>
                <ul><li>- <b>Journal:</b> The Lancet</li><li>- <b>Publication Date:</b> April 30, 2022</li><li>- <b>Study Type:</b> Phase 3, multicentre, open-label, randomised trial with a 2x2 factorial design.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What was the specific dose of prednisone used in the PEACE-1 trial, and how does it compare to the dose used for metastatic castration-resistant prostate cancer (mCRPC)?</li><li>- In the ADT with docetaxel population, what was the median CRPC-free survival for the group receiving abiraterone versus the group that did not?</li><li>- What percentage of patients in the control group (SOC without abiraterone) eventually received a next-generation hormonal therapy after progression?</li><li>- What was the minimum PSA value used to define mCRPC in this trial, even without radiographic progression?</li><li>- Besides hypertension, which other grade ≥3 adverse event was notably more frequent in the abiraterone group compared to the control group in the ADT + docetaxel population?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Background & Rationale</strong></summary>
            <div>
                <ul><li>- Treatment for <u>de novo metastatic castration-sensitive prostate cancer (mCSPC)</u> has evolved beyond Androgen Deprivation Therapy (ADT) alone.</li><li>- Current standards of care (SOC) involve adding <b>docetaxel</b>, a second-generation androgen receptor axis inhibitor (e.g., <b>abiraterone</b>, <b>apalutamide</b>, <b>enzalutamide</b>), or radiotherapy to ADT.</li><li>- The key unanswered question was whether <u>combining</u> these new therapies (i.e., triplet therapy) could provide further clinical benefits.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>PEACE-1 Study Design</strong></summary>
            <div>
                <ul><li>- A multicentre, open-label, randomised, phase 3 study with a <b>2x2 factorial design</b>.</li><li>- Aimed to evaluate the efficacy and safety of adding <b>abiraterone</b> and/or <b>radiotherapy</b> to the Standard of Care (SOC).</li></ul>
                
        <details>
            <summary><strong>Patient Population</strong></summary>
            <div>
                <ul><li>- <b>1173</b> male patients with <u>de novo</u> metastatic prostate adenocarcinoma.</li><li>- ECOG performance status of <q>0–1</q> (or 2 if due to bone pain).</li><li>- ADT initiated for no more than <q>3 months</q> before randomisation.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Randomization & Arms (1:1:1:1)</strong></summary>
            <div>
                <ul><li>- <b>Arm 1:</b> Standard of Care (SOC).</li><li>- <b>Arm 2:</b> SOC + Radiotherapy.</li><li>- <b>Arm 3:</b> SOC + Abiraterone.</li><li>- <b>Arm 4:</b> SOC + Radiotherapy + Abiraterone.</li></ul>
                
        <details>
            <summary><strong>Evolution of Standard of Care (SOC) During Trial</strong></summary>
            <div>
                <ul><li>- Initially (2013): SOC was <b>ADT alone</b>.</li><li>- Amendment 1 (Oct 2015): SOC allowed for <b>ADT + docetaxel</b> after CHAARTED/STAMPEDE results.</li><li>- Amendment 2 (Aug 2017): SOC mandated <b>ADT + docetaxel</b> for all new patients after LATITUDE/STAMPEDE results for abiraterone.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment Regimens</strong></summary>
            <div>
                <ul><li>- <b>ADT:</b> Continuous (GnRH agonist/antagonist or orchiectomy).</li><li>- <b>Docetaxel:</b> <q>75 mg/m²</q> IV every 3 weeks for <q>6 cycles</q>.</li><li>- <b>Abiraterone:</b> <q>1000 mg</q> orally once daily.</li><li>- <b>Prednisone:</b> <q>5 mg</q> orally twice daily (total <q>10mg/day</q>, similar to the dose for mCRPC).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Endpoints</strong></summary>
            <div>
                <ul><li>- <b>Co-primary endpoints:</b></li><li>- Radiographic Progression-Free Survival (rPFS).</li><li>- Overall Survival (OS).</li><li>- <b>Key secondary endpoint:</b> Castration-Resistant Prostate Cancer (CRPC)-free survival.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Efficacy Results</strong></summary>
            <div>
                <ul><li>- Median follow-up for OS was <q>4.4 years</q>.</li><li>- No significant interaction was found between abiraterone and radiotherapy, allowing for a pooled analysis of abiraterone's effect.</li></ul>
                
        <details>
            <summary><strong>Overall Population (ADT +/- Docetaxel)</strong></summary>
            <div>
                <ul><li>- Compares all patients receiving abiraterone (n=583) vs. all patients not receiving abiraterone (n=589).</li></ul>
                
        <details>
            <summary><strong>Radiographic Progression-Free Survival (rPFS)</strong></summary>
            <div>
                <ul><li>- Median rPFS improved from <q>2.2 years</q> to <q>4.5 years</q>.</li><li>- <b>46%</b> risk reduction of progression or death.</li><li>- HR: <q><b>0.54</b></q> (99.9% CI 0.41–0.71; p<0.0001).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Overall Survival (OS)</strong></summary>
            <div>
                <ul><li>- Median OS improved from <q>4.7 years</q> to <q>5.7 years</q>.</li><li>- <b>18%</b> risk reduction of death.</li><li>- HR: <q><b>0.82</b></q> (95.1% CI 0.69–0.98; p=0.030).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><u>Population of Interest:</u> ADT + Docetaxel (Triplet Therapy)</strong></summary>
            <div>
                <ul><li>- This is the key comparison for establishing triplet therapy as a new SOC (n=355 with abiraterone vs. n=355 without).</li></ul>
                
        <details>
            <summary><strong>Radiographic Progression-Free Survival (rPFS)</strong></summary>
            <div>
                <ul><li>- Median rPFS more than doubled from <q>2.0 years</q> to <q>4.5 years</q>.</li><li>- <b>50%</b> risk reduction of progression or death.</li><li>- HR: <q><b>0.50</b></q> (99.9% CI 0.34–0.71; p<0.0001).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Overall Survival (OS)</strong></summary>
            <div>
                <ul><li>- Median OS: Not reached vs. <q>4.4 years</q>.</li><li>- <b>25%</b> risk reduction of death.</li><li>- HR: <q><b>0.75</b></q> (95.1% CI 0.59–0.95; p=0.017).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Subgroup Analysis by Disease Burden</strong></summary>
            <div>
                <ul><li>- High Burden Definition: Visceral metastases or <q>≥4 bone lesions with ≥1 outside the vertebral bodies/pelvis</q>.</li></ul>
                
        <details>
            <summary><strong><b>High-Volume</b> Disease</strong></summary>
            <div>
                <ul><li>- <u>Clear OS benefit</u> with triplet therapy.</li><li>- Median OS improved from <q>3.5 years</q> to <q>5.1 years</q>.</li><li>- <b>28%</b> risk reduction of death (HR <q>0.72</q>, p=0.019).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Low-Volume</b> Disease</strong></summary>
            <div>
                <ul><li>- <u>No conclusive OS benefit</u> yet (data immature).</li><li>- HR for OS: <q>0.83</q> (p=0.66).</li><li>- However, a major benefit in rPFS was observed (HR <q>0.58</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Other Key Endpoints</strong></summary>
            <div>
                <ul><li>- <b>CRPC-free survival:</b> Median improved from <q>1.45 years</q> to <q>3.21 years</q> (HR 0.38).</li><li>- <b>Prostate-cancer-specific survival:</b> Improved with abiraterone (HR <q>0.69</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Safety & Toxicity (ADT + Docetaxel Population)</strong></summary>
            <div>
                <ul><li>- Adding abiraterone to ADT+Docetaxel resulted in a <u>modest increase in toxicity</u>.</li><li>- Grade ≥3 AEs: <q>63%</q> with abiraterone vs. <q>52%</q> without.</li><li>- Fatal (Grade 5) AEs: <q>2%</q> with abiraterone vs. <q>1%</q> without.</li></ul>
                
        <details>
            <summary><strong>Specific Grade ≥3 Adverse Events (Abiraterone vs. Control)</strong></summary>
            <div>
                <ul><li>- <b>Hypertension:</b> <q>22%</q> vs. <q>13%</q> (largest difference).</li><li>- <b>Hepatotoxicity (aminotransferase increase):</b> <q>6%</q> vs. <q>1%</q>.</li><li>- <b>Febrile Neutropenia:</b> <q>5%</q> vs. <q>5%</q> (<u>no increase</u>).</li><li>- <b>Neutropenia:</b> <q>10%</q> vs. <q>9%</q> (<u>no increase</u>).</li><li>- <b>Fatigue:</b> <q>3%</q> vs. <q>4%</q> (<u>no increase</u>).</li><li>- <b>Peripheral Neuropathy:</b> <q>1%</q> vs. <q>2%</q> (<u>no increase</u>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Note on Drug Interactions</strong></summary>
            <div>
                <ul><li>- No evidence of increased chemotherapy-related side effects.</li><li>- Suggests <u>no significant drug-drug interaction</u> between abiraterone and docetaxel affecting toxicity.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Discussion & Clinical Implications</strong></summary>
            <div>
                <ul><li>- PEACE-1 is the <u>first trial</u> to show an OS benefit for a triplet systemic therapy (ADT + Docetaxel + Abiraterone) in de novo mCSPC.</li></ul>
                
        <details>
            <summary><strong>New Standard of Care</strong></summary>
            <div>
                <ul><li>- Triplet therapy should be considered a <u>new SOC</u> for patients with <b>high-volume</b> mCSPC who are fit for docetaxel.</li><li>- For <b>low-volume</b> disease, the decision is less clear due to immature OS data, requiring shared decision-making.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Upfront Combination vs. Sequential Therapy</strong></summary>
            <div>
                <ul><li>- Benefit was seen even though <q>over 80%</q> of the control group received a next-generation hormonal therapy upon progression.</li><li>- This suggests upfront combination is <u>superior to sequential administration</u> of these agents.</li></ul>
                
        <details>
            <summary><strong>Definition of Progression in Control Arm</strong></summary>
            <div>
                <ul><li>- Investigators were allowed to start salvage therapy early.</li><li>- CRPC was defined by radiographic progression or a confirmed PSA rise with a minimum value of just <q>0.50 ng/mL</q> and castrate testosterone.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Limitations & Unanswered Questions</strong></summary>
            <div>
                <ul><li>- Open-label design.</li><li>- Does not answer if triplet therapy is superior to ADT + abiraterone alone.</li><li>- Unclear if findings apply to <u>metachronous</u> (relapsing) mCSPC, as only de novo patients were included.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Conclusion</strong></summary>
            <div>
                <ul><li>- The triplet combination of <b>ADT, docetaxel, and abiraterone</b> improved both <u>overall survival</u> and <u>radiographic progression-free survival</u> in men with de novo mCSPC.</li><li>- This triplet therapy could become a <b>new standard of care</b>, especially for patients with high-volume disease.</li><li>- The toxicity profile was manageable, with a modest increase primarily in <b>hypertension</b>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
